Xeris Biopharma Holdings, Inc. · NASDAQ:XERS
Xeris Biopharma — Technical Presentation (September 2026)
24 slides from Xeris Biopharma's technical presentation, Sep 9, 2026
Slide 1: XP-8121 Program Overview
XP-8121 Program Overview September 9, 2026
Slide 2: Today’s Agenda
Today’s Agenda Welcome & Introductions 1 Allison Wey — SVP, Investor Relations Becoming the Next Great Biopharmaceutical Company 2 John Shannon – Chairman and Chief Executive Officer KOL Perspective: The Realities of Hypothyroidism Care 3 David Robertson, MD – Endocrinologist and Thyroid Specialist
Slide 3: Important Disclosures
Important Disclosures Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans, opportunities, and prospects for the
Slide 4: Becoming the Next Great Biopharmaceutical Company
Becoming the Next Great Biopharmaceutical Company John Shannon Chairman & Chief Executive Officer
Slide 5: Our Path to Become the Next Great Biopharmaceutical Company
Our Path to Become the Next Great Biopharmaceutical Company Our strategy is straightforward — and we believe it is working 2035+ 2030 Continued growth & pipeline execution 2026 Continued growth & pipeline execution ▪ Multi-billion in total revenue ▪ Positioned to be the next great Built a fast-growi
Slide 6: XP-8121: A Potential Transformative Medicine in Clinical Development
XP-8121: A Potential Transformative Medicine in Clinical Development Hypothyroidism Is A Common Disease Significant Unmet With A Wide Range Of Symptoms Medical Need Hair thinning/loss ~20% Sleep disturbance Depression/mood Cognitive dysfunction disturbance Cold intolerance Menstrual irregularities F
Slide 7: Streamlined Development and Strategy Designed to Maximize Long-Term Commercial Value
Streamlined Development and Strategy Designed to Maximize Long-Term Commercial Value What you will hear today Cornerstone trial expected to initiate by year-end, fully aligned with FDA feedback on endpoints ON TRACK and statistical power; data expected late 2028, approval and launch anticipated in 2
Slide 8: The Realities of Hypothyroidism Care
The Realities of Hypothyroidism Care David Robertson, MD Endocrinologist and Key Opinion Leader Cornerstone Investigator
Slide 9: The Clinical Reality
The Clinical Reality The unmet need is real 1 Every week, patients doing everything right remain with thyroid-stimulating hormone (“TSH”) outside range We need new therapies 2 Oral therapy may not reliably deliver what the guidelines plainly require Passionate about the program 3 Joining Cornerstone
Slide 10: Comprehensive Development Plan
Comprehensive Development Plan Anh Nguyen, MD Chief Medical Officer
Slide 11: Addressing Clinical Limitations to Potentially Unlock Better Long-term Patient Outcomes
Addressing Clinical Limitations to Potentially Unlock Better Long-term Patient Outcomes WHERE CURRENT DISEASE MANAGEMENT HAS STALLED WHAT XP-8121 IS EXPECTED TO DELIVER Limited therapeutic innovation An intuitive therapy: once-weekly subcutaneous Decades have passed with little meaningful change to
Slide 12: Comprehensive Plan to Support XP-8121 Approval and Maximize Clinical Adoption
Comprehensive Plan to Support XP-8121 Approval and Maximize Clinical Adoption 1 APPROVAL 2 SAFETY & DOSING 3 DIFFERENTIATION 2 ▪ Cornerstone is designed to ▪ Capstone will evaluate dose ▪ Touchstone is expected to show demonstrate equivalence to oral conversion in pediatrics further efficacy in pati
Slide 13: Cornerstone: Phase 3 Clinical Study Design
Cornerstone: Phase 3 Clinical Study Design 500 Participants >50 U.S. sites 54 wks Treatment duration 15% Non-inferiority margin SCREENIN G XP-8121 once-weekly subcutaneous (“SC”) therapy 48 & 54 WEEKS Well-controlled Primary Endpoint adults & adolescents R LABS MEASURED & TREATMENT CHANGES ALLOWED E
Slide 14: Building Differentiation for XP-8121
Building Differentiation for XP-8121 Real-world Evidence TO PROVE THE THERAPEUTIC BENEFIT WHERE IT MATTERS MOST TO QUANTIFY THE UNMET NEED & CALL TO ACTION Population Establish the clinical unmet need Patients with inconsistent control, who are inadequately treated despite Quantify the consequences
Slide 15: Anticipated Clinical Milestones Through 2030
Anticipated Clinical Milestones Through 2030 2026 2027 2028 2029 2030 Last patient out + Initiate Study Approval topline results Last patient out + Initiate Study Safety & Dosing topline results Approval & Commercial Launch Last patient out + Initiate Study Differentiation topline results REAL-WORLD
Slide 16: Unmet Need, Moat, & Commercial Readiness
Unmet Need, Moat, & Commercial Readiness Joshua Bennett Josh Bennett Head of Strategy
Slide 17: Despite Treatment, Millions of Patients Remain Biochemically Uncontrolled
Despite Treatment, Millions of Patients Remain Biochemically Uncontrolled THE GUIDELINES ARE CLEAR1 3–5M ~20% patients out of range on any given of all hypothyroid patients, already day diagnosed and treated, are not well controlled THE ORAL ROUTE what disrupts oral levothyroxine absorption Underlyi
Slide 18: A Product Developed to Solve a High Unmet Need
A Product Developed to Solve a High Unmet Need THE BARRIER THE SOLUTION THE COMPREHENSIVE PROGRAM Why nobody has done this Every component already on the market Why Phase 3 succeeds Inherently unstable Levothyroxine Strong clinical record Formulating a stable, concentrated liquid Approved and prescr
Slide 19: A Well-defined Patient Population Enables Rapid Identification and Conversion at Launch
A Well-defined Patient Population Enables Rapid Identification and Conversion at Launch Exceptional KOL engagement signals strong clinical demand for A UNIQUE OPPORTUNITY WITH A SUBSTANTIAL MARKET XP-8121 and supports a differentiated approach. ALREADY ALREADY ALREADY MARKET RESEARCH DIAGNOSED TREAT
Slide 20: Leveraging Existing Commercial Infrastructure; Supports Efficient Launch Preparation, & Build-out
Leveraging Existing Commercial Infrastructure; Supports Efficient Launch Preparation, & Build-out Demonstrate the Need Reach Prescribers Ensure Patient Access Data defining the unmet need, paired Identifying the endocrinologists who Coverage and prior authorization with KOL engagement, bring those s
Slide 21: The Case for XP-8121
The Case for XP-8121 Joshua Bennett John Shannon Chairman & Chief Executive Officer
Slide 22: A Transformative Opportunity to Redefine Care
A Transformative Opportunity to Redefine Care PEAK NET REVENUE POTENTIAL1 A well-established unmet need A comprehensive program designed for $1–3B high probability of success positions Xeris to become the next great biopharmaceutical company Data generation that differentiates and maximizes adoption
Slide 23: Q&A
Q&A John Shannon Dr. Anh Nguyen Joshua Bennett Chairman & Chief Chief Medical Officer Head of Strategy Executive Officer Steve Pieper Allison Wey Chief Financial Officer SVP, Investor Relations Copyright © 2021-2026 Xeris Pharmaceuticals, Inc. All rights reserved.
Slide 24: Thank You
Thank You Nasdaq: XERS | xerispharma.com Copyright © 2021-2026 Xeris Pharmaceuticals, Inc. All rights reserved.
Xeris Biopharma Holdings — Technical Presentation (September 2026) on 6ix